Background and Purpose-Haptoglobin (Hp) is an acute phase plasma protein protecting tissues from oxidative damage. It exists in 2 variant alleles (hp1/hp2) giving rise to 3 protein isoforms with different biochemical properties and efficiency to limit oxidative stress. We previously found that hp2 variant is associated with stroke risk in the patients with carotid stenosis and the risk of ischemic cardiovascular events in a general population cohort. This study examined the hypothesis that Hp genotype is associated with general cardiovascular risk in patients with stroke. Methods-Hp was genotyped in SAM study (Helsinki Stroke Aging Memory, n=378). A total of 1426 individuals ascertained from a nationally representative cross-sectional health survey served as population controls. Results-Hp genotype frequencies were 15.6% (hp1-1), 44.2% (hp1-2), and 40.2% (hp2-2) in patients with stroke. During a mean of 7.5-year follow-up after first-ever stroke, hp2 carriers had a substantially higher rate of cardiac deaths (24.5% versus 8.5%; P=0.006) and a trend toward more fatal strokes (23.5% versus 13.6%; P=0.122). The combined risk of ischemic cardiovascular deaths was 2.4-fold higher among hp2 carriers (95% confidence interval, 1.28-4.43) after adjustment for major cardiovascular risk factors. Conclusions-Hp2 allele is associated with premature ischemic cardiovascular deaths after first-ever ischemic stroke. 
T he principal defense against the deleterious effects of free hemoglobin (Hb) released during hemorrhage is provided by haptoglobin (Hp), an acute phase plasma protein and important physiological antioxidant. 1, 2 Hp regulates vascular health by several means. It binds to Hb forming a soluble complex which is cleared through endocytosis by the macrophage scavenger receptor CD163 initiating anti-inflammatory signaling cascades. 1 Heme is degraded by heme oxygenase 1 to carbon monoxide (CO), iron (Fe 2+ ), and biliverdin to be further metabolized to bilirubin, a potent tissue antioxidant. CO functions as a slow vasodilator and can replace NO in damaged atherosclerotic vessel wall. Fe 2+ has widespread effects on gene expression through the network of iron-response elements and proteins. To this end, Hp-CD163-heme oxygenase 1 pathway has been shown to influence important vasoregulatory targets, such as vascular tone, balance between apoptosis and proliferation of vessel wall cells, and protection against oxidative damage and inflammation related to local Hb accumulation.
The Hp locus in the chromosome, 16q22, is polymorphic. Hp gene carries a common 1.7 kb copy number variant resulting in 2 variant alleles in humans, hp1 and hp2. They give rise to 3 protein isoforms, Hp1-1, Hp1-2, and Hp2-2, which differ remarkably in their biochemical properties and also in their efficiency to counteract oxidative stress. Hp1-1 occurs as a small circular molecule that binds Hb in 3:1 proportion and efficiently clear free Hb. In contrast, Hp1-2 and Hp2-2 form sheet structures or complex linear structures, respectively, where both binding to Hb and CD163 receptor are compromised. Hp2 allele is common in some subtropical regions and may yield selective advantage given to its greater protection against malaria falciparum infection. 3 However, it is becoming obvious that other properties of hp2 allele present cardiometabolic risks to the aging population of the modern world. In addition to attenuated heme-recycling and antioxidant properties, Hp2-2 binds with high affinity to human apolipoprotein A-I [4] [5] [6] and apolipoprotein E 7 in high-density lipoprotein and thereby seems to interfere with cholesterol levels and reverse cholesterol transport (RCT). In line, hp2 allele has been associated with vascular complication in diabetic subjects. 2, [8] [9] [10] Our earlier observations demonstrated that hp2 allele (Hp1-2 and Hp2-2 protein phenotypes) associate with the risk of ischemic stroke in patients with carotid stenosis (ie, symptomatic carotid stenosis) and also with the risk of acute myocardial infarction and ischemic stroke in a general population cohort. 11 Staals et al 12 have associated Hp1-1 phenotype with lacunar stroke in young patients devoid of silent lacunar infarcts or extensive white matter lesions. Hp1-1 genotype was also linked with increased stroke risk in type I diabetics, in a prospective study by Costacou et al. 13 This study was therefore designed to examine whether hp2 allele genotypes associate with specific stroke subtypes and are there variants that accelerate myocardial infarction, stroke, and cardiovascular death.
Patients and Methods
More details on study cohorts and genotyping can be found in the online-only Data Supplement.
Helsinki Stroke Aging Memory Study
Stroke subjects belong to SAM study (Helsinki Stroke Aging Memory), which is a prospective, cross-sectional study examining the cognitive, functional, and emotional consequences of ischemic stroke. 14, 15 The cohort includes 486 consecutive patients aged 55 to 85 years who were admitted to Helsinki University Hospital between 1993 and 1995 because of suspected stroke and fulfilling the preset inclusion criteria. Patients underwent comprehensive clinical and cognitive evaluation. DNA was available from 378 patients and brain magnetic resonance imaging from 396 patients. The patients were followed for a mean of 7.5±4.0 years until September 2006 using extensive national registers. 15 Long-term survival data in September 2006 were obtained from Statistics Finland. Of the original 486 patients, 347 (71.4%) had died. The causes of death based on International Classification of Diseases, Ninth Revision and Tenth Revision classifications were obtained and divided further into cardiac, brain-related (ischemic stroke, bleeding, dementia), cancer, infection, trauma, and other categories. In 9 cases, the cause of death could not be determined, and these were excluded when analyzing the data. The demographics of SAM patients are presented in Table 1 and the frequencies of ischemic cardiovascular deaths in Table 2 .
Health 2000 Survey
As a population control, we used participants derived from the nationally representative Health 2000 survey, which is an epidemiological health examination survey performed in Finland from fall 2000 to spring 2001 by the National Public Health Institute (www. terveys2000.fi) as detailed also in our previous study. 11 The overall study cohort was a 2-stage stratified cluster sample (8028 patients) representing the entire Finnish population aged ≥30 years. Here, we included 1516 patients aged 45 to 74 from the Cardiovascular diseases, substudy of the Health 2000 survey. These subjects were invited to undergo a thorough cardiovascular examinations including carotid ultrasound. The original sample size was 1867, and the participation rate was 82%. DNA was available from 1426 individuals.
Genotyping
DNA was extracted from peripheral blood leukocytes. Hp genotypes were determined by a modification of a method described by Koch et al. 16 Details are given in the online-only Data Supplement. (Table II in the online-only Data Supplement). A receiver operating characteristic curves were created by plotting the probability distributions for 4 logistic regression models described in Table III in the online-only Data Supplement. Significance of the difference between the areas under receiver operating characteristic curves was calculated by the method described by Hanley and McNeil.
Statistical Methods
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Ethical Issues
The SAM study has been approved by the Ethics committee of the Department of Clinical Neurosciences, Helsinki University Hospital and Health 2000 survey by the Ethics committees of Hospital District of Helsinki and Uusimaa and the National Public Health Institute.
Results
The genotype frequencies were 15.6% for hp1-1, 44.2% for hp1-2, and 40.2% for hp2-2 in the SAM cohort and 14.3%, 48.6%, and 37.1%, respectively, in the Health 2000 cohort (Table 3 ). Both distributions were within Hardy-Weinberg equilibrium (P=0.247 in SAM and P=0.361 in Health 2000). The allele frequencies of hp1 were 0.38 and 0.39 and hp2 were 0.62 and 0.61 in SAM and Health 2000, respectively. There were no significant differences in genotype or allele frequencies between the patients with stroke and population controls (Table 3) .
There were no differences in the frequency of risk factors between stroke patients with different Hp genotypes with the exception that male hp2-2 carriers smoked less often than male hp1-1 and hp1-2 carriers (P=0.017; Table 1 ).
Male patients with stroke displayed higher frequency of hp2-2 genotype than female patients with stroke (46.0% versus 34.4%; P=0.042) who on the other hand had more hp1-2 genotype (50.3% versus 38.1%). In women, a history of acute myocardial infarction was associated with hp2 allele (hp1-2 and hp2-2; P=0.016). There were no differences in Hp genotypes between different stroke subtypes classified according to TOAST (Trial of ORG 10172 in Acute Stroke Treatment; Table 1 There was a trend toward higher all-cause mortality in hp1-2 and hp2-2 carriers (P=0.061, data not shown).
There were only 82 diabetic stroke patients, and in their group, hp2 allele was associated with increased risk of ischemic cardiovascular death. The risk was highest in the carriers of hp2-2 genotype (OR, 8.51; 95% CI, 1.55-46.86) but was also clearly elevated in hp1-2 (OR, 5.57; 95% CI, 1.06-29.36) compared with hp1-1 subjects.
When adjusted for major cardiovascular risk factors (age, sex, hypertension, diabetes mellitus, atrial fibrillation, and low-density lipoprotein cholesterol), the combined risk of ischemic cardiovascular death was 2.4-fold elevated in hp2 carriers (95% CI, 1.28-4.43). The size of the effect of hp1-2 and hp2-2 genotypes was comparable to classical cardiovascular risk factors (Table II in Table III in the online-only Data Supplement) increased the area under curve from 0.699 to 0.727, but this did not reach statistical significance. 
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Discussion
In this study, we demonstrate evidence for the association of hp2 allele of the haptoglobin gene with ischemic cardiovascular death after first-ever ischemic stroke. Overall, the association was strongest in female and diabetic stroke patients. We note a consistent trend toward better discrimination power when hp2 allele is added to other cardiovascular risk factors (Figure) . This raises the possibility that Hp genotype or phenotype could be used in risk stratification to identify stroke survivors who need enhanced monitoring of cardiovascular risk factors and more intensive management strategies. The results from this stroke cohort replicate our earlier finding in a population-based cross-sectional health survey, the Health 2000 study, where hp2 allele was associated with a 2.2-fold elevated risk of ischemic cardiovascular events during the 10 years follow-up period of middle-aged volunteers. 11 This study confirms that the association between hp2 allele and ischemic cardiovascular events also applies to high-risk stroke population. Our earlier finding of an association of hp2 allele with symptomatic carotid stenosis and the tight association between myocardial infarction seen both in our earlier study and in this stroke cohort supports the hypothesis that hp2 allele increases the risk of sudden atherothrombotic events both in cerebral and cardiac circulation. However, we could not confirm an association of Hp genotypes with pathogenic stroke subtypes classified according to TOAST, not between hp1-1 and lacunar stroke reported by Staals et al 12 neither hp2 and large vessel disease in general.
Initially, haptoglobin Hp2-2 phenotype was associated with a larger size of myocardial infarct. 18 After this, Hp geno/ phenotypes have been tested against different cardiovascular manifestations, but later reports 3 conflicted in reporting this association to Hp1-2 19 or Hp1-1 phenotype, 20 or reporting no association. 21 There are several possible explanations for these inconsistent findings. Except for the Framingham Heart Offspring Study (n=3273) 19 and Bruneck Study (n=806), 21 the sample sizes in all older studies were relatively small, up to 200 patients. The definition of outcome varied across the studies. In the Bruneck Study, the combined cardiovascular disease outcome was uncommon (n=123) and included intracerebral hemorrhage, the pathogenesis of which clearly differs from that of myocardial infarction and is driven by hypertension rather than by atherosclerosis. In Framingham Heart Offspring Study, angina pectoris patients without a history of myocardial infarction were also included. In our study, we did not detect association between Hp genotypes and intracerebral hemorrhage, including subarachnoid hemorrhage (data 2 test between hp1-1 and hp2 genotypes. §Odds ratios with 95% confidence intervals of outcome for genotype hp1-2 (hp1-1 as a reference genotype) adjusted for age and sex if not included in the model. ‖Odds ratios with 95% confidence intervals of outcome for genotype hp2-2 (hp1-1 as a reference genotype) adjusted for age and sex if not included in the model. not shown) and based on our previous study, 11 the association is strongest between acute atherotrombotic cardiovascular events, such as myocardial infarction and large artery atherosclerotic stroke, rather than chronic atherosclerotic manifestations. This substantiates the importance of careful definition of phenotype in the genetic studies of stroke, the pathogenesis of which is heterogeneous compared with myocardial infarction.
During the last 2 decades, the focus has shifted to the effect of Hp polymorphism in diabetic individuals because hp2 genotype seems to aggravate the deleterious vascular effects during hyperglycemia. 2, 22, 23 The association was first reported in a cohort of type I diabetics where hp2 allele was associated with diabetic nephropathy and the prevalence of restenosis after coronary angioplasty. 24 In Strong Heart study, a longitudinal population-based study of American Indians, the hp2-2 genotype was associated with an OR of 5.0 to cardiovascular disease compared with hp1-1 in diabetic subjects, whereas hp1-2 showed intermediate risk. 8 In a recent meta-analysis of 5 studies involving 1829 patients with diabetes mellitus, the pooled OR for cardiovascular disease was 2.03 (95% CI, 1.46-2.81) among hp2-2 genotype subjects when compared with subjects with other genotypes. 22 Furthermore, the risk increases among individuals with elevated HbA(1c). 23 In the present stroke cohort, the frequency of ischemic cardiovascular deaths was significantly higher in both diabetic and nondiabetic hp2 carriers compared with hp1-1 carriers, but hp2-2 seemed to be more strongly associated in diabetics whereas hp1-2 in nondiabetics. Similar trend was noted in the Framingham Heart Offspring Study. 19 This could be explained by different biochemical properties of Hp1-2 and Hp2-2 protein isoforms but remains to be confirmed in future studies. On the contrary, we did not find association between hp1 allele and small vessel disease (by TOAST classification) in diabetics which was reported earlier by Costacou et al 13 in type I diabetic patients. However, the number of diabetics in our study cohort was low (n=86) and we could not differentiate between type I and II diabetes mellitus, and thus our study is underpowered to detect specific associations in type I diabetics.
Haptoglobin hp2 genotype may increase cardiovascular risk by impairing cellular capacity to alleviate heme-induced oxidative stress and interfering with RCT, thereby promoting accumulation of oxidatively modified low-density lipoprotein into the vessel wall. Hp2-2 has been shown to lead to an impairment of Hb clearance in atherosclerotic plaques after intraplaque hemorrhage and increased oxidative, inflammatory, and angiogenic responses, 25, 26 as well as oxidation of low-density lipoprotein. 27 Hb-Hp2-2 complexes bind tightly to apolipoprotein A-1 of high-density lipoprotein while high-density lipoprotein becomes proinflammatory and loses its capacity for RCT. 5, 6 Furthermore, the Hp gene cluster has emerged as an important locus influencing cholesterol levels. [28] [29] [30] Recently, it was suggested that Hp locus drives cholesterol levels by regulating Hp serum levels and oxidation of apolipoprotein E, thus representing another route of effect on RCT. 31 Could the detrimental effect of hp2 be alleviated in highrisk individuals? Interesting recent data suggest that the impaired RCT process in hp2-2 individuals could be enhanced by antioxidant α-tocopherol (ie, vitamin E treatment). In a meta-analysis of 2110 diabetic patients in 3 trials, the OR for nonfatal myocardial infarction, stroke, or cardiovascular death was 0.66 (95% CI, 0.48-0.9) in favor of the vitamin E treatment in patients with hp2-2. 22 This effect was genotype specific; α-tocopherol improved high-density lipoprotein function in hp2-2 carriers but appeared to affect lipid peroxides and lipoprotein subfractions among hp1 allele carriers adversely. 32 α-Tocopherol has not yet been tested in nondiabetics, and its effect on heterozygote hp1-2 individuals is unclear. In principle, this kind of personalized genotype-directed treatment of individuals at high risk of cardiovascular events, such as in the secondary prevention of acute myocardial infarction and ischemic stroke, could be tested for clinical efficacy.
Limitations
There are certain limitations in this study. The large proportion of stroke cases with undetermined pathogenesis may be the reason why we cannot conclude on the association of hp2 (Table II in the online-only Data Supplement). B, Receiver operating characteristic (ROC) curves were created by plotting the probability distributions for 4 logistic regression models in Table III in the online-only Data Supplement.
allele with specific TOAST stroke subtypes in SAM cohort. At the time of the recruitment of the SAM cohort (in 1990s), carotid duplex or ambulatory ECG were not included in the diagnostic workup of patients with stroke in our hospital, for which we do not have true knowledge on the prevalence of carotid stenosis or atrial fibrillation. Another limitation is the cohort size that limits the power for subgroup analysis. On the other hand, the strengths of our study are the extent of brain magnetic resonance imaging and long follow-up time which all minimize the number of stroke mimics in our cohort. Finally, there is a possibility of selection/survival bias because the SAM cohort was formed 3 months after the index stroke when patients with most severe strokes have died. 15 This may have led to a decreased number of patients with stroke, especially females with severe atherothrombotic and cardioembolic strokes, and may even underlie the relative paucity of hp2-2 females in the SAM cohort compared with men (Table 2 ). If such bias exists, it would have led to underestimation of the effect of hp2 allele rather than type I error.
Summary
We show that hp2 allele of the haptoglobin gene increases the risk of ischemic cardiovascular death after first-ever ischemic stroke by 2.4-fold even after adjustment with major cardiovascular risk factors. The risk is high for both hp1-2 and hp2-2 genotypes but especially elevated in hp1-2 females and in hp2-2 diabetics. We found no significant difference in Hp genotypes between patients with stroke and population controls or between stroke subtypes classified according to TOAST. 
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